Beginning in 2010, more than 1000 women filed lawsuits against Merck for allegedly failing to warn them about atypical femoral fracture associated with the use of the bisphosphonate alendronate, a serious adverse event. On May 20, 2019, the US Supreme Court decided the consolidated case of Merck Sharp & Dohme Corp v Albrecht et al and further commented on instances in which pharmaceutical manufacturers may be held liable for failing to warn patients about the adverse effects of drugs approved by the US Food and Drug Administration (FDA).1 This case has far-reaching implications for patients, physicians, and the pharmaceutical industry.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Johnston MC, Boumil MM, Curfman G. A New Supreme Court Ruling on Drug Liability. JAMA. 2019;322(7):607–608. doi:10.1001/jama.2019.8515
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: